14th May 2007 09:48
ABCAM Plc14 May 2007 For immediate release 14 May 2007 ABCAM PLC ("Abcam" or "the Company") Shareholding Cambridge UK, 14 May 2007: Abcam plc announces that in accordance with the FSA'sDisclosure and Transparency Rules, the Company has been notified that, as at 10May 2007, N W Brown Nominees Limited had an indirect interest in voting rightsover 5,035,760 ordinary shares of 1p each in the Company amounting toapproximately 14.5% of the issued share capital of the Company. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500James Black Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcamwas admitted to AIM in November 2005 and trades under the ticker symbol ABC.The Company produces and distributes its own and third party produced antibodiesto academic and commercial users throughout the world with product informationprovided and ordering available through the Company's website, www.abcam.com.The antibodies are sold under the Abcam brand name. The Company's vision is tobuild the largest online antibody resource in the world while also ensuring thatthe antibodies are of high quality and commercially viable. Abcam now has anonline catalogue of approximately 30,000 products, most of which are antibodies,from over 200 suppliers supported by up-to-date and detailed technical datasheets, which are created by the Company. The Company currently employs 120staff in its three operating companies. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
ABC.L